Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Perspective

Perspective on the Role of Four Beta-blockers in Heart Failure

Author(s): Asim Ahmed Elnour Ahmed*

Volume 17, Issue 2, 2022

Published on: 28 October, 2021

Page: [85 - 89] Pages: 5

DOI: 10.2174/2772432816666211029103324

Abstract

Background: The current recommendations of the American College of Cardiology/ American Heart Association and a previous Bayesian analysis clearly show a mortality benefit with the use of β- blockers in chronic HF, especially for bisoprolol, carvedilol, and sustained-release metoprolol succinate.

Objective: The main objective was to report the evidence on the use of the afore-mentioned β-blockers in subjects with heart failure and to characterize the stages of heart failure in response to the four different β-blockers. Furthermore, it shed light on the patient’s satisfaction and improved quality of life using the afore-mentioned β-blockers in subjects with heart failure.

Methods: The current perspective presented the clinical outcomes, including hospitalization, morbidity, mortality, patient’s satisfaction, and quality of life, of four beta (β)-blockers, namely bisoprolol, carvedilol, metoprolol succinate, and nebivolol in different stages of heart failure.

Results: The use of these three agents should be recommended for all stable subjects with current or previous symptoms of heart failure and heart failure with reduced ejection fraction unless there is any contraindication. The fore-mentioned β-blockers (bisoprolol, carvedilol, and metoprolol succinate) can be initiated early, even in stable and symptom-free (at rest) subjects with heart failure. β-blockers in heart failure should be commenced at small doses and then titrated upward as tolerated to achieve the desired clinical effects on heart rate and symptom control.

Conclusion: Cardiologists should weigh the benefit-risk in subjects with heart failure and other coexisting cardiovascular problems such as atrial fibrillation and diabetes.

Keywords: Bisoprolol, carvedilol, metoprolol succinate, nebivolol, heart failure, beta blocker.

« Previous Next »
Graphical Abstract

[1]
Vinereanu D, Spinar J, Pathak A, Kozlowski D. Role of metoprolol succinate in the treatment of heart failure and atrial fibrillation: A systematic review. Am J Ther 2020; 27(2): e183-93.
[http://dx.doi.org/10.1097/MJT.0000000000001043] [PMID: 31385823]
[2]
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334(21): 1349-55.
[http://dx.doi.org/10.1056/NEJM199605233342101] [PMID: 8614419]
[3]
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353(9169): 2001-7.
[http://dx.doi.org/10.1016/S0140-6736(99)04440-2] [PMID: 10376614]
[4]
Lechat P, Brunhuber KW, Hofmann R. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353(9146): 9-13.
[http://dx.doi.org/10.1016/S0140-6736(98)11181-9] [PMID: 10023943]
[5]
Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: A review. JAMA 2020; 324(5): 488-504.
[http://dx.doi.org/10.1001/jama.2020.10262]
[6]
Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 2010; 26(3): 615-29.
[http://dx.doi.org/10.1185/03007990903533681] [PMID: 20067434]
[7]
Pathak A, Mrabeti S. β-blockade for patients with hypertension, ischemic heart disease or heart failure: Where are we now? Vasc Health Risk Manag 2021; 17: 337-48.
[http://dx.doi.org/10.2147/VHRM.S285907] [PMID: 34135591]
[8]
Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3): 215-25.
[http://dx.doi.org/10.1093/eurheartj/ehi115] [PMID: 15642700]
[9]
Sharp RP, Gales BJ. Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction. Ther Adv Urol 2017; 9(2): 59-63.
[http://dx.doi.org/10.1177/1756287216685027] [PMID: 28203288]
[10]
Tsutsui H, Momomura SI, Masuyama T, et al. Tolerability, efficacy, and safety of bisoprolol vs. Carvedilol in Japanese patients with heart failure and reduced ejection fraction　- The CIBIS-J Trial. Circ J 2019; 83(6): 1269-77.
[http://dx.doi.org/10.1253/circj.CJ-18-1199] [PMID: 30956267]
[11]
Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: Results from the COPERNICUS Study. JAMA 2003; 289(6): 712-8.
[http://dx.doi.org/10.1001/jama.289.6.712] [PMID: 12585949]
[12]
Gorman A. Carvedilol is not superior to metoprolol for heart failure patients when given at equivalent doses. Clin Res Prac 2019; 5(2)eP1891
[http://dx.doi.org/10.22237/crp/1567555680]
[13]
Choi KH, Lee GY, Choi J-O, et al. The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction. Korean J Intern Med (Korean Assoc Intern Med) 2019; 34(5): 1030-9.
[http://dx.doi.org/10.3904/kjim.2018.009] [PMID: 30317846]
[14]
Briasoulis A, Palla M, Afonso L. Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure. Am J Cardiol 2015; 115(8): 1111-5.
[http://dx.doi.org/10.1016/j.amjcard.2015.01.545] [PMID: 25708861]
[15]
Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106(17): 2194-9.
[http://dx.doi.org/10.1161/01.CIR.0000035653.72855.BF] [PMID: 12390947]
[16]
Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: Network meta-analysis. BMJ 2013; 346: f55.
[http://dx.doi.org/10.1136/bmj.f55] [PMID: 23325883]
[17]
Zhang X, Shen C, Zhai S, Liu Y, Yue WW, Han L. A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure. Exp Ther Med 2016; 12(4): 2489-96.
[http://dx.doi.org/10.3892/etm.2016.3657] [PMID: 27703506]
[18]
Ziff OJ, Samra M, Howard JP, et al. Beta-blocker efficacy across different cardiovascular indications: An umbrella review and meta-analytic assessment. BMC Med 2020; 18(1): 103.
[http://dx.doi.org/10.1186/s12916-020-01564-3] [PMID: 32366251]
[19]
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American college of cardiology/American heart association task force on practice guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation 2005; 112(12): e154-235.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.167586] [PMID: 16160202]
[20]
Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357(9266): 1385-90.
[http://dx.doi.org/10.1016/S0140-6736(00)04560-8] [PMID: 11356434]
[21]
Philippides GJ. Managing the post-myocardial infarction patient with asymptomatic left ventricular dysfunction. Cardiology 2006; 105(2): 95-107.
[http://dx.doi.org/10.1159/000089970] [PMID: 16340202]
[22]
Goldberg LR, Jessup M. Stage B heart failure: Management of asymptomatic left ventricular systolic dysfunction. Circulation 2006; 113(24): 2851-60.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.600437] [PMID: 16785351]
[23]
McMurray J, Køber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: Results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45(4): 525-30.
[http://dx.doi.org/10.1016/j.jacc.2004.09.076] [PMID: 15708698]
[24]
Klapholz M. Beta-blocker use for the stages of heart failure. Mayo Clin Proc 2009; 84(8): 718-29.
[http://dx.doi.org/10.4065/84.8.718] [PMID: 19648389]
[25]
Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362(9377): 7-13.
[http://dx.doi.org/10.1016/S0140-6736(03)13800-7] [PMID: 12853193]
[26]
Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94(11): 2807-16.
[http://dx.doi.org/10.1161/01.CIR.94.11.2807] [PMID: 8941106]
[27]
Fonarow GC. Profile of carvedilol controlled-release: A new once-daily formulation of carvedilol. Expert Opin Pharmacother 2006; 7(18): 2533-46.
[http://dx.doi.org/10.1517/14656566.7.18.2533] [PMID: 17150007]
[28]
Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344(22): 1659-67.
[http://dx.doi.org/10.1056/NEJM200105313442202] [PMID: 11386264]
[29]
Kojima T, Hikoso S, Yasumura Y. The Effect of beta blockers on maintaining quality of life at one year after discharge in patients with heart failure with preserved ejection fraction-from the pursuit Hfpef registry Circulation 2019; 140(Suppl_1): A12936
[30]
Fitzgerald AA, Powers JD, Ho PM, et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail 2011; 17(8): 664-9.
[http://dx.doi.org/10.1016/j.cardfail.2011.04.011] [PMID: 21807328]
[31]
Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American college of cardiology foundation/American heart association task force on practice guidelines: Developed in collaboration with the international society for heart and lung transplantation. Circulation 2009; 119(14): 1977-2016.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064] [PMID: 19324967]
[32]
Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134(7): 550-60.
[http://dx.doi.org/10.7326/0003-4819-134-7-200104030-00008] [PMID: 11281737]

Rights & Permissions Print Cite
Article Metrics
42
2
1
1
© 2024 Bentham Science Publishers | Privacy Policy